TWI875682B - 使用趨化激素受體2(ccr2)拮抗劑及pd-1/pd-l1抑制劑之組合療法 - Google Patents

使用趨化激素受體2(ccr2)拮抗劑及pd-1/pd-l1抑制劑之組合療法 Download PDF

Info

Publication number
TWI875682B
TWI875682B TW107133664A TW107133664A TWI875682B TW I875682 B TWI875682 B TW I875682B TW 107133664 A TW107133664 A TW 107133664A TW 107133664 A TW107133664 A TW 107133664A TW I875682 B TWI875682 B TW I875682B
Authority
TW
Taiwan
Prior art keywords
inhibitor
alkyl
group
chemokine receptor
ccr2
Prior art date
Application number
TW107133664A
Other languages
English (en)
Chinese (zh)
Other versions
TW201922287A (zh
Inventor
詹姆士 Ｊ 坎貝爾
振華 繆
湯姆斯 J 沙爾
伊斯雷爾 查羅
世杰 李
克里斯汀 瑪麗 詹森
羅瑾德 斯穎
凱倫 埃布斯沃思
Original Assignee
美商卡默森屈有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商卡默森屈有限公司 filed Critical 美商卡默森屈有限公司
Publication of TW201922287A publication Critical patent/TW201922287A/zh
Application granted granted Critical
Publication of TWI875682B publication Critical patent/TWI875682B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW107133664A 2017-09-25 2018-09-25 使用趨化激素受體2(ccr2)拮抗劑及pd-1/pd-l1抑制劑之組合療法 TWI875682B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762562952P 2017-09-25 2017-09-25
US62/562,952 2017-09-25

Publications (2)

Publication Number Publication Date
TW201922287A TW201922287A (zh) 2019-06-16
TWI875682B true TWI875682B (zh) 2025-03-11

Family

ID=65810578

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107133664A TWI875682B (zh) 2017-09-25 2018-09-25 使用趨化激素受體2(ccr2)拮抗劑及pd-1/pd-l1抑制劑之組合療法

Country Status (15)

Country Link
US (2) US11304952B2 (enExample)
EP (1) EP3687525B1 (enExample)
JP (2) JP7453139B2 (enExample)
KR (1) KR102677442B1 (enExample)
CN (2) CN111712242B (enExample)
AR (1) AR112831A1 (enExample)
AU (2) AU2018335486B8 (enExample)
BR (1) BR112020005284A2 (enExample)
CA (1) CA3075638A1 (enExample)
IL (1) IL273188B2 (enExample)
MA (1) MA50665A (enExample)
MX (1) MX2020003192A (enExample)
SG (1) SG11202002119QA (enExample)
TW (1) TWI875682B (enExample)
WO (1) WO2019060820A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135168B (zh) 2015-05-21 2021-07-20 凯莫森特里克斯股份有限公司 Ccr2调节剂
US20190275015A1 (en) * 2017-09-25 2019-09-12 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
CN112105353B (zh) 2018-01-08 2024-04-19 凯莫森特里克斯股份有限公司 Ccr2拮抗剂治疗实体瘤的方法
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
EP3755311A4 (en) 2018-02-22 2021-11-10 ChemoCentryx, Inc. INDANAMINE AS PD-L1 ANTAGONISTS
KR102890201B1 (ko) 2019-07-10 2025-11-24 케모센트릭스, 인크. Pd-l1 억제제로서의 인단
PH12022550877A1 (en) 2019-10-16 2023-03-27 Chemocentryx Inc Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
JP7736678B2 (ja) 2019-10-16 2025-09-09 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド
CN114907267A (zh) * 2021-02-08 2022-08-16 中国科学院上海药物研究所 用于抗肿瘤的药物组合

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
DE69110787T2 (de) 1990-02-28 1996-04-04 Medtronic, Inc., Minneapolis, Minn. Intraluminale prothese mit wirkstoffeluierung.
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AR034257A1 (es) 2000-06-30 2004-02-18 Du Pont Pharm Co Compuesto ureido, composicion farmaceutica que lo comprende y metodo para modular la actividad del receptor de quimiocinas
AU8334501A (en) 2000-08-17 2002-02-25 Merck & Co Inc Cyclopentyl modulators of chemokine receptor activity
EP1604982A1 (en) 2001-07-02 2005-12-14 AstraZeneca AB Intermediates for the preparation of piperidine derivatives useful as modulators of chemokine receptor activity
ATE404538T1 (de) 2002-04-29 2008-08-15 Merck & Co Inc Tetrahydropyranylcyclopentyltetrahydroisochino- linmodulatoren der chemokinrezeptoraktivität
TWI262077B (en) 2002-04-29 2006-09-21 Merck & Co Inc Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
WO2003092586A2 (en) 2002-04-29 2003-11-13 Merck & Co., Inc. Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
US20060030582A1 (en) 2002-04-29 2006-02-09 Demartino Julie Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
US7491737B2 (en) 2002-10-30 2009-02-17 Merck & Co., Inc. Heterarylpiperidine modulators of chemokine receptor activity
AU2004215409B2 (en) 2003-02-24 2008-11-20 Merck Sharp & Dohme Corp. Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity
CA2519220A1 (en) 2003-03-18 2004-09-30 Merck & Co., Inc. Amino cyclobutylamide modulators of chemokine receptor activity
AU2004231087B2 (en) 2003-04-15 2007-01-04 Merck Sharp & Dohme Corp. Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
WO2004094371A2 (en) 2003-04-17 2004-11-04 Merck & Co., Inc. Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
US20060205761A1 (en) 2003-06-06 2006-09-14 Catherine Abbadie Ccr-2 antagonists for treatment of neuropathic pain
UA81365C2 (en) 2003-10-27 2007-12-25 Merck & Co Inc Ccr-2 antagonist salt, method for modulation of chemokine receptor activity, method for treating (variants) and pharmaceutical composition
AR045875A1 (es) 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2
AU2004313486A1 (en) 2004-01-02 2005-07-28 Merck & Co., Inc. Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity
AU2005214319B2 (en) 2004-02-12 2009-02-19 Merck Sharp & Dohme Corp. Amino heterocyclic modulators of chemokine receptor activity
CN1950085A (zh) 2004-05-11 2007-04-18 因赛特公司 作为趋化因子受体调节剂的3－(4－杂芳基环己基氨基)环戊烷羧酰胺
UY29219A1 (es) 2004-11-22 2006-04-28 Incyte Corp Sales de la n-(2- (((3r)-1-(trans-4-hidroxi-4-(6-metoxipiridin-3-il)-cilohexil) pirrolidin-3-il)amino)-2-oxoetil)-3- (trifluorometil) benzamida
JP2008526861A (ja) 2005-01-06 2008-07-24 メルク エンド カムパニー インコーポレーテッド 炎症性障害を治療するための薬剤併用療法および医薬組成物
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
US7671062B2 (en) 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
KR101617050B1 (ko) 2007-07-12 2016-05-02 케모센트릭스, 인크. 염증의 치료를 위한 ｃｃｒ2 조절물질로서 융합된 헤테로아릴 피리딜과 페닐 벤젠술폰아마이드
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
MX2011003195A (es) 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
CA2745969C (en) 2008-12-10 2017-04-25 Janssen Pharmaceutica Nv 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
KR20120061060A (ko) 2009-04-16 2012-06-12 얀센 파마슈티카 엔.브이. Ｃｃｒ2의 4-아제티디닐-1-헤테로아릴-사이클로헥산 길항제
CN102459227B (zh) 2009-04-17 2014-08-20 詹森药业有限公司 Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂
PL2513093T3 (pl) 2009-12-17 2015-03-31 Centrexion Therapeutics Corp Nowi antagoniści receptora CCR2 i ich zastosowanie
ES2449379T3 (es) 2010-02-09 2014-03-19 Bristol-Myers Squibb Company Derivados de bencilpirrolidinona como moduladores de la actividad de receptores de quimiocinas
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
AU2011268375B2 (en) 2010-06-17 2015-02-05 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
WO2012121361A1 (ja) 2011-03-10 2012-09-13 第一三共株式会社 ジスピロピロリジン誘導体
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
US8822460B2 (en) 2012-04-06 2014-09-02 Janssen Pharmaceutica Nv Fused cyclopentyl antagonists of CCR2
CA2873402C (en) 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
KR102129636B1 (ko) 2012-05-31 2020-07-03 제넨테크, 인크. Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법
HK1208236A1 (en) 2012-06-22 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ccr2
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
CN105451770B (zh) 2013-08-20 2020-02-07 默沙东公司 使用PD-1拮抗剂和dinaciclib的组合治疗癌症
JP6417419B2 (ja) 2013-09-04 2018-11-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫調節剤として有用な化合物
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
BR112017003718B1 (pt) 2014-09-11 2023-04-11 Bristol-Myers Squibb Company Inibidores macrocíclicos das interações de proteína/proteína de pd- 1/pd-l1 e cd80(b7-1)/pd-l1
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
CN108135168B (zh) 2015-05-21 2021-07-20 凯莫森特里克斯股份有限公司 Ccr2调节剂
WO2017165125A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer
US10195188B2 (en) 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
US10251888B2 (en) 2016-06-13 2019-04-09 Chemocentryx, Inc. Method of treating pancreatic cancer
US10639284B2 (en) 2016-06-27 2020-05-05 Chemocentryx, Inc. Immunomodulator compounds
CA3058944A1 (en) * 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
US20190275015A1 (en) 2017-09-25 2019-09-12 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
CN112105353B (zh) 2018-01-08 2024-04-19 凯莫森特里克斯股份有限公司 Ccr2拮抗剂治疗实体瘤的方法
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
CA3088542A1 (en) 2018-01-22 2019-07-25 Bristol-Myers Squibb Company Compositions and methods of treating cancer
US20200297708A1 (en) 2019-03-19 2020-09-24 Chemocentryx, Inc. Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor

Also Published As

Publication number Publication date
JP2023181168A (ja) 2023-12-21
AU2024204212A1 (en) 2024-07-11
SG11202002119QA (en) 2020-04-29
RU2020112755A (ru) 2021-10-28
WO2019060820A1 (en) 2019-03-28
AU2024204212B2 (en) 2025-12-18
AR112831A1 (es) 2019-12-18
KR20200110300A (ko) 2020-09-23
BR112020005284A2 (pt) 2020-09-24
US11304952B2 (en) 2022-04-19
JP7453139B2 (ja) 2024-03-19
IL273188A (en) 2020-04-30
EP3687525A1 (en) 2020-08-05
JP2020535144A (ja) 2020-12-03
CA3075638A1 (en) 2019-03-28
AU2018335486A8 (en) 2024-12-05
IL273188B2 (en) 2023-03-01
MA50665A (fr) 2020-08-05
CN111712242A (zh) 2020-09-25
CN111712242B (zh) 2023-11-24
CN118267479A (zh) 2024-07-02
TW201922287A (zh) 2019-06-16
MX2020003192A (es) 2020-07-29
AU2018335486B8 (en) 2024-12-05
RU2020112755A3 (enExample) 2022-03-31
US20230023075A1 (en) 2023-01-26
EP3687525A4 (en) 2021-10-13
US20190134049A1 (en) 2019-05-09
AU2018335486B2 (en) 2024-07-04
KR102677442B1 (ko) 2024-06-20
IL273188B (en) 2022-11-01
EP3687525B1 (en) 2025-10-29
AU2018335486A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
TWI875682B (zh) 使用趨化激素受體2(ccr2)拮抗劑及pd-1/pd-l1抑制劑之組合療法
JP7611189B2 (ja) Ｐｄ－１阻害剤又はｐｄ－ｌ１阻害剤と組み合わせてｃｃｒ１アンタゴニストを投与することによる腫瘍負荷の低減
US20240285593A1 (en) Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
US20230404986A1 (en) Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor
RU2796863C2 (ru) Комбинированная терапия с использованием антагониста хемокинового рецептора 2 (CCR2) и ингибитора PD-1/PD-L1
WO2020191240A1 (en) Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor
CA3019391C (en) Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
HK40004572B (en) Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
BR122024013223A2 (pt) Composição de antagonistas do ccr1 e inibidores de pd-1 ou inibidores de pd-l1, kit e seus usos